When the Notified Body suspends your certificate mid-audit

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

This is not a theoretical scenario. It happens more often than manufacturers expect. And it does not start with the suspension itself. It starts months or years earlier, during the initial conformity assessment, when clinical evaluation deficiencies were closed with promises, updates, or partial evidence that looked acceptable at the time.

The suspension decision follows a pattern. The Notified Body identifies a gap that undermines the benefit-risk profile or challenges the validity of the clinical evidence. The manufacturer tries to respond. But the response requires data that does not exist yet, or requires a level of analysis that should have been part of the original CER. The Notified Body cannot maintain the certificate while the foundational clinical claim is uncertain.

So the certificate is suspended. And the market access stops.

What triggers a suspension decision

MDR Article 46 gives Notified Bodies the authority to suspend, restrict, or withdraw certificates when they identify non-conformities that affect safety or performance. The clinical evaluation is one of the most common areas where this happens.

Not every clinical gap leads to suspension. Minor documentation issues, delayed PMCF reports, or formatting problems get flagged as non-conformities. The manufacturer responds, closes the finding, and moves on. But some gaps go deeper. They challenge the validity of the conformity claim itself.

Here is what I observe in real files:

The Notified Body realizes that the equivalence claim used to support the clinical evaluation is based on a predicate device that is not actually equivalent. The materials differ. The indications differ. The clinical performance data does not cover the same patient population. The manufacturer believed the devices were equivalent because they looked similar and had the same intended use statement. But the clinical evaluator at the Notified Body applied MDCG 2020-5 criteria and found fundamental differences that were never addressed.

The clinical data package relies on literature studies that do not actually demonstrate the claimed clinical benefit. The studies included in the CER show safety, but not effectiveness for the specific indication. Or they show effectiveness in a different population. Or the outcome measures used in the studies do not align with the claims made in the IFU. The manufacturer assumed that any positive clinical study was sufficient. The Notified Body reviewer sees a disconnect between the evidence and the claims.

The risk-benefit analysis in the CER is based on clinical data that is no longer representative. The device was modified. The intended use was expanded. The patient population changed. But the clinical evaluation was not updated to reflect these changes. The manufacturer updated the technical file and the risk management file, but the CER still references the old design or the old indication. The Notified Body sees a mismatch between what the device is now and what the clinical evidence supports.

These are not administrative issues. These are fundamental problems with the clinical justification for CE marking. And when the Notified Body identifies them, suspension becomes a real possibility.

Why manufacturers do not see it coming

Most manufacturers do not expect suspension because they believe their clinical evaluation is compliant. They passed the initial audit. They received a certificate. They responded to previous non-conformities. They assumed the clinical file was acceptable.

But compliance is not static. The Notified Body does not review the entire clinical file in every audit. During the initial conformity assessment, the focus is on whether the clinical evaluation demonstrates conformity with the general safety and performance requirements. During surveillance, the focus shifts. The Notified Body checks whether the clinical evaluation is being maintained. Whether PMCF data is being generated and analyzed. Whether new information has emerged that changes the benefit-risk profile.

Sometimes, the gaps were always there. They were noted as minor non-conformities during the initial review, and the manufacturer provided a response that was sufficient to close the finding at that time. But the underlying issue was never fully resolved. The clinical data was marginal. The equivalence justification was weak. The PMCF plan was generic. The Notified Body accepted the response with the expectation that the manufacturer would improve the clinical file over time.

Then, during a surveillance audit, the Notified Body revisits the topic. They see that the clinical evaluation has not evolved. The PMCF data is still generic. The literature review has not been updated. The benefit-risk analysis still relies on the same weak evidence. And now, with more experience and a clearer understanding of the device and the market, the Notified Body realizes that the original clinical justification was insufficient.

Another common scenario is auditor rotation. A new clinical evaluator reviews the file during surveillance. This evaluator has a different perspective or applies MDCG guidance more strictly. They see issues that the previous reviewer did not flag. The manufacturer is caught off guard because they believed the file was stable.

What happens when suspension is issued

The immediate consequence is loss of market access. The manufacturer cannot place new devices on the market under the suspended certificate. Existing devices in the supply chain can still be used, but no new shipments can leave the facility. Distributors stop ordering. Customers lose confidence. Revenue drops.

The manufacturer must respond to the suspension notice. The Notified Body specifies the reasons for suspension and the conditions for lifting it. Usually, this means updating the clinical evaluation, providing additional clinical data, or conducting new clinical investigations to fill the evidence gap.

But here is the problem: generating new clinical evidence takes time. If the suspension is based on missing clinical data, the manufacturer cannot resolve it in a few weeks. A clinical investigation requires protocol development, ethics approval, patient recruitment, data collection, and analysis. That is months or years. A literature review update might be faster, but only if relevant studies exist. And if the equivalence claim is invalid, the entire clinical strategy must be rebuilt.

In some cases, the manufacturer tries to respond with the same evidence package, reframed or re-analyzed. They argue that the clinical data is actually sufficient if interpreted differently. They provide additional justification for the equivalence claim. They expand the discussion in the CER. But if the Notified Body has already concluded that the evidence is insufficient, this type of response rarely lifts the suspension. The gap is substantive, not editorial.

Meanwhile, competitors continue to operate. Customers switch to alternative devices. Market share is lost. And the cost of suspension goes far beyond the revenue impact. There are contractual penalties with distributors. There are reputational consequences with clinicians and procurement departments. There are internal pressures from leadership who do not understand why a compliant device suddenly lost its certificate.

The underlying pattern in suspended files

When I review files that have led to suspension, I see a recurring pattern. The clinical evaluation was built to pass the audit, not to support the device throughout its lifecycle. The focus was on compliance at a single point in time, not on maintaining a robust clinical evidence base.

The equivalence justification was stretched. The manufacturer wanted to avoid a clinical investigation, so they identified a predicate device that was close enough. They acknowledged some differences but argued they were not clinically significant. The Notified Body accepted this during the initial review, often with conditions. But those conditions were never fully met. And when the surveillance audit revisited the topic, the equivalence claim collapsed under scrutiny.

The literature review was narrow. The manufacturer included only studies that supported their claims. They excluded studies that showed conflicting results or highlighted risks. They did not include a State of the Art analysis that contextualized their device within the broader clinical evidence landscape. The Notified Body accepted the literature review initially because it was not obviously incomplete. But over time, new studies emerged. New risks were reported in similar devices. And the manufacturer did not update the CER to reflect this evolving knowledge.

The benefit-risk analysis was qualitative and generic. It stated that benefits outweigh risks without quantifying either. It did not address specific patient groups or use scenarios where the balance might shift. It did not consider alternative treatments or the clinical context in which the device would actually be used. The Notified Body accepted this during the initial audit because it met the minimum structural requirements. But during surveillance, when the evaluator digs deeper, the analysis is revealed as superficial.

How to avoid the path to suspension

The best defense is not compliance theater. It is building a clinical evaluation that actually reflects the clinical reality of your device. That means accepting uncertainty where it exists. Committing to generate the data needed to resolve that uncertainty. And maintaining the clinical file as a living document that evolves with your device and the available evidence.

If your device relies on equivalence, treat the equivalence justification as the foundation of your clinical strategy. Apply MDCG 2020-5 rigorously. Do not stretch the definition of equivalence to avoid a clinical investigation. If your predicate device is not truly equivalent in all relevant characteristics, acknowledge the differences and generate data to address them. Equivalence is not a shortcut. It is a specific pathway with strict criteria, and if those criteria are not met, the entire clinical evaluation is at risk.

Your PMCF plan must be designed to generate data that can validate or challenge the assumptions in your CER. It should not be a passive monitoring system. It should include active data collection on clinical performance, user feedback, and real-world outcomes. And when that data reveals gaps or contradictions, update the CER immediately. Do not wait for the next audit.

Your literature review must be comprehensive and updated regularly. Include studies that challenge your claims, not just studies that support them. Address conflicting evidence explicitly. Explain why certain risks are acceptable in your device or why certain benefits are achievable despite negative findings in similar devices. The State of the Art analysis should show that you understand the full clinical landscape, not just the favorable parts.

Your benefit-risk analysis must be specific and quantified wherever possible. Use real data from PMCF, clinical investigations, or published studies. Break down the analysis by patient subgroup, use scenario, and clinical context. Show that you have thought through when and where your device provides the most benefit and where the risks might outweigh the benefits. This level of detail protects you during surveillance because it demonstrates depth of understanding, not just compliance with a template.

What comes next

In the next part of this series, we will look at how Notified Bodies assess your response to clinical evaluation non-conformities. Because the gap between a minor finding and a suspension decision is often determined by how you respond when the first warning appears. Most suspensions are not sudden. They are the endpoint of a pattern that started with an inadequate response to an earlier audit finding.

Understanding how Notified Bodies evaluate your corrective actions and your evidence updates gives you the ability to prevent escalation. And it forces you to see your clinical evaluation through the eyes of the reviewer who has the authority to suspend your certificate.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.